Chikungunya is an acute febrile illness caused by an alpha virus technically called as CHIK virus. A smaller size of CHIK virus E1 coat protein -11 kDa was expressed in prokaryotic expression system. The recombinant protein was purified and confirmed by western blot analysis. The positions of the antigenic domain in the protein were identified and the immunoreactivity of recombinant protein with anti-CHIK IgM antibodies was ascertained. The antigen showed an 88% sensitivity and 100% specificity by Indirect ELISA. No cross reactivity of the antigen was observed with anti-Dengue virus serum samples. The results strongly support that the recombinant CHIK coat protein could be used as a diagnostic antigen for the detection of Chikungunya by Indirect ELISA. The relevance of a smaller size recombinant antigen highlights its large scale application in serodiagnosis of CHIK virus since bacterial expression is more simple and cost effective than eukaryotic system.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jim.2011.07.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objectives: Arboviruses pose a significant global health challenge. This study investigated the seroprevalence of major human arboviral infections, including yellow fever (YFV), dengue (DENV), Crimean-Congo hemorrhagic fever (CCHF), Rift Valley fever (RVF), West Nile virus (WNV), and chikungunya (CHIK), in Darfur region from September to December 2018. ELISA-IgM was used to detect antibodies.
View Article and Find Full Text PDFA safe insect-based chikungunya fever vaccine affords rapid and durable protection in cynomolgus macaques.
NPJ Vaccines
December 2024
Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Eilat (EILV)/chikungunya virus (CHIKV), an insect-based chimeric alphavirus was previously reported to protect mice months after a single dose vaccination. The underlying mechanisms of host protection are not clearly defined. Here, we assessed the capacity of EILV/CHIKV to induce quick and durable protection in cynomolgus macaques.
View Article and Find Full Text PDFKnowledge, attitude, and practices of the community about Chikungunya in selected Districts of Afar Region, Northeast Ethiopia; its implications for controlling the disease: a community-based quantitative and qualitative cross-sectional study.
BMC Public Health
December 2024
Aklilu Lemma Institute of Pathobiology, Addis Ababa University, P.O.Box 1176, Addis Ababa, Ethiopia.
Background: Chikungunya (CHIK) is a viral disease spread by Aedes mosquitoes in tropical and subtropical countries, including Ethiopia. It is important to educate communities and implement behavioral and social interventions to prevent and control the spread of disease. This study assessed the community's knowledge, attitude, and practices (KAP) about CHIK disease in the Afar Region, Northeast Ethiopia.
View Article and Find Full Text PDFA comprehensive seroepidemiology of dengue and chikungunya arboviruses in Iran, 2020-2023.
Virol J
November 2024
Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, 69 Pasteur Ave., Tehran, 1316943551, Iran.
Aim: Dengue virus (DENV) and Chikungunya virus (CHIKV) are the most common arthropod-borne viruses (Arboviruses) globally. So far, no autochthonous cases of DENV and CHIKV infections have been reported in Iran. Nevertheless, due to the recent identification of Aedes aegypti in the south and Aedes albopictus in the north of Iran, the country is at a serious risk of local outbreaks of these infections.
View Article and Find Full Text PDFChikungunya vaccine development, challenges, and pathway toward public health impact.
Vaccine
December 2024
International Vaccine Institute, South Korea; CIRI - Centre International de Recherche en Infectiologie, Team GIMAP, Université Jean Monnet, France. Electronic address:
Chikungunya is a neglected tropical disease of growing public health concern with outbreaks in more than 114 countries in Asia, Africa, Americas, Europe, and Oceania since 2004. There are no specific antiviral treatment options for chikungunya virus infection. This article describes the chikungunya vaccine pipeline and assesses the challenges in the path to licensure, access, and uptake of chikungunya vaccines in populations at risk.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!